exoRehab | 리임버서블 AI 기반 원격 치료 모니터링 + 웨어러블

Post-surgery patients find it difficult to consistently continue rehabilitation exercises at home, and existing physical therapy relies on subjective assessments, making it difficult to accurately understand the patient's condition.

Therapists have to estimate a patient's exercise performance or muscle strength recovery based on intuition, and the lack of standardized data limits the verification of rehabilitation effectiveness and early intervention. In particular, the absence of objective indicators for early detection and management of muscle function decline, such as sarcopenia in the elderly, is a problem.

exoRehab is a wearable device with built-in surface electromyography (EMG) and 9-axis IMU sensors that measures a patient's muscle activity and joint movements in real-time, and uses a proprietary AI algorithm to calculate digital biomarkers such as Muscle Function Index (MFI) to provide objective rehabilitation assessment.

This MFI index quantifies muscle function within 5 minutes, providing faster and more consistent results compared to existing manual evaluations, and its reliability has been recognized through multi-center studies. It also automatically records Medicare remote therapeutic monitoring codes (CPT 98975–98981) to support insurance claim documentation, lowering the barrier to adoption by allowing hospitals to claim fees without additional staff.

Medical institutions such as rehabilitation hospitals and physical therapy clinics (B2B)These are the main customers, with professional therapists prescribing and using exoRehab for patient rehabilitation. Patients borrow the wearable device from the hospital and exercise at home, while therapists monitor patient data through a web dashboard.

It is provided through medical institutions rather than being directly purchased by individual consumers, and is currently being piloted in some clinics in the US and Korea.

As a medical device, it complies with ISO 13485 quality management and FDA standards to meet regulatory requirements, and has also completed US FCC certification, completing preparations for launch. With the US market launch scheduled immediately after CES 2026, regulatory barriers are low.

There is a high potential for expansion into new medical fields such as supporting the diagnosis of sarcopenia in the elderly – in fact, exoRehab's AI software has been designated as an innovative medical device by the Korean Ministry of Food and Drug Safety, recognizing its potential for use in assisting with the diagnosis of sarcopenia. In addition, the remote rehabilitation platform is expected to expand into other wellness areas such as fitness and insurance linkage, in addition to healthcare.

The CES Innovation Award has internationally recognized its technology and innovation, and the increased effectiveness of remote rehabilitation has been highly evaluated. The product has a high degree of completion (completed over 20 pilot tests) and is expected to be commercialized soon, demonstrating excellent technological maturity. The comprehensive solution of AI, wearable devices, and insurance claim linkage has raised market expectations.

However, the speed of adoption by healthcare professionals and verification of insurance claim effectiveness in the healthcare market are pointed out as key to actual business success. Overall, the evaluation is that "it is very positive based on the CES showcase, and market verification is just beginning."